Lumir Ventures has invested in Scopio Labs to support the development of innovative cell morphology solutions aimed at improving disease diagnosis and treatment access.
Target Information
Lumir Ventures is excited to announce its investment in Scopio Labs, a pioneering provider of the world's first full-field digital cell morphology solution. Scopio Labs specializes in accelerating the detection and diagnosis of diseases, thereby allowing for quicker access to life-saving treatments for patients. Founded in 2015 and headquartered in Tel Aviv, Scopio has successfully raised $84 million to date and currently employs a workforce of 90 individuals across both Israel and the United States.
With a vision to revolutionize standard healthcare practices, Scopio Labs is committed to enhancing first-line diagnostic testing. The company harnesses the capabilities of Full Field™ Imaging and artificial intelligence to analyze cellular morphology with unprecedented scale and depth, significantly improving diagnostic efficiency.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Israel
The healthcare industry in Israel is known for its advanced technologies and innovation, making it a prominent player in the global healthcare sector. The country has consistently demonstrated a strong focus on research and development, alongside a vib
Similar Deals
Harel Insurance & Finance, European Innovation Council (EIC) Fund → Omnix Medical
2025
Lumir Ventures
invested in
Scopio Labs
in
in a Other deal